INSIGHTS
No marketing stories — only the facts patients actually need to verify: which treatments are available in China, how long they take, what they cost, and where the pathway most often breaks.
Four CAR-T products are approved in China, covering lymphoma, leukaemia and multiple myeloma. This note covers eligibility, assessment criteria, manufacturing timeline, cost ranges and key risks.
Read the noteNeither is simply "better photon therapy" — both are particle beams. The choice depends on tumour location, nearby organs at risk, prior radiotherapy and long-term risk in children.
Read the noteFour steps, how long each takes, the documents required, visa types and common pitfalls.
Read the note